Industry Payments to Physicians for Opioid Products, 2013-2015

To identify payments that involved opioid products from the pharmaceutical industry to physicians. We used the Open Payments program database from the Centers for Medicare and Medicaid Services to identify payments involving an opioid to physicians between August 2013 and December 2015. We used medi...

Full description

Saved in:
Bibliographic Details
Published in:American journal of public health (1971) 2017-09, Vol.107 (9), p.1493-1495
Main Authors: Hadland, Scott E, Krieger, Maxwell S, Marshall, Brandon D L
Format: Article
Language:English
Subjects:
Abuse
Addictions
AJPH Research
Analgesics, Opioid - economics
Analgesics, Opioid - therapeutic use
Anesthesiology
Brand names
Buprenorphine
Centers for Medicare and Medicaid Services (U.S.)
Disclosure - legislation & jurisprudence
Disease control
Drug abuse
Drug Industry - economics
Drug Industry - organization & administration
Drug overdose
Drugs
Education
Ethics
FDA approval
Fentanyl
Food
Formulations
Gift Giving
Government programs
Health care
Health Professionals
Humans
Medicaid
Medical personnel
Medicare
Medicine
Narcotics
Nonsteroidal anti-inflammatory drugs
Opioids
Pain
Pain management
Payments
Pharmaceutical industry
Pharmacists
Physicians
Physicians - economics
Physicians - organization & administration
Practice Patterns, Physicians' - economics
Public health
Skewed distributions
Substance abuse treatment
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To identify payments that involved opioid products from the pharmaceutical industry to physicians. We used the Open Payments program database from the Centers for Medicare and Medicaid Services to identify payments involving an opioid to physicians between August 2013 and December 2015. We used medians, interquartile ranges, and ranges as a result of heavily skewed distributions to examine payments according to opioid product, abuse-deterrent formulation, nature of payment, state, and physician specialty. During the study, 375 266 nonresearch opioid-related payments were made to 68 177 physicians, totaling $46 158 388. The top 1% of physicians received 82.5% of total payments in dollars. Abuse-deterrent formulations constituted 20.3% of total payments, and buprenorphine marketed for addiction treatment constituted 9.9%. Most payments were for speaking fees or honoraria (63.2% of all dollars), whereas food and beverage payments were the most frequent (93.9% of all payments). Physicians specializing in anesthesiology received the most in total annual payments (median = $50; interquartile range = $16-$151). Approximately 1 in 12 US physicians received a payment involving an opioid during the 29-month study. These findings should prompt an examination of industry influences on opioid prescribing.
ISSN:0090-0036
1541-0048
DOI:10.2105/AJPH.2017.303982